Novartis' phase three study of Leqvio for ASCVD patients showed significant LDL cholesterol reduction.

Novartis' phase three study of cholesterol-management drug, Leqvio, showed positive results as a standalone treatment for ASCVD patients. The trial met its primary endpoints, demonstrating significant LDL cholesterol reduction. Novartis plans to present the results and share them with regulatory agencies. Leqvio is being explored in additional studies for ASCVD prevention, with results expected between 2024-2027.